“…Approximately 70% of the prescriptions of RT for benign diseases in German RT departments account for degenerative disorders [35], and annually, > 3,500 heel spur patients are treated in Germany [24]. Objective mechanisms influencing the intensity of inflammation and modulating the cell functions being responsible for the release and maintenance of the inflammatory reaction have been demonstrated by numerous in vitro [11,12,23,29,30,31] and in vivo studies [10,13,19,38]. The response rates of 87.7% obtained at 6-month follow-up in both of our study groups demonstrated an equivalent efficacy of the two different dose-fractionation schedules resulting in a highly significant improvement of the sum score.…”